Although a positive trend was observed for patients with a CPS ≥10 in the efficacy endpoints of ORR, PFS, and OS, the findings of these trials suggest that ICI monotherapy could offer limited survival benefits, potentially enhanced in patients with PD-L1-positive mTNBC.
← all excerpts
Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.
1
—
—